Metropolis Healthcare announced its business update for the December quarter (Q3 FY25) on Monday, January 6, highlighting a strong performance with 11% year-on-year (YoY) revenue growth. This growth was driven by an increase in patient volumes, test volumes, a favourable product mix, and realisation benefits.
Despite seasonally lower revenue growth and constrained operating leverage, the company recorded a modest YoY improvement in margins, showcasing its operational efficiency.
The B2C segment continued to lead the company’s growth trajectory, posting a 15% YoY revenue increase. This performance was attributed to Metropolis Healthcare’s industry-leading testing capabilities and strong brand appeal among end consumers. To sustain momentum, the company is considering price increases in its B2C offerings in select cities, effective Q4 FY25.
The B2B segment also grew, albeit at a lower rate, with revenue rising in low double digits YoY. However, the company noted that growth was impacted by a decline in the institutional business, which is not a core focus area.
Metropolis Healthcare’s Truhealth wellness and bundling segment emerged as the fastest-growing category during the quarter, achieving a remarkable 25% YoY growth rate. This underscores the company’s success in diversifying its portfolio and tapping into consumer demand for preventive health and wellness solutions.
The company remains financially robust, with no debt on its balance sheet and cash reserves of ₹200 crore as of December 31, 2024.
On January 06, 2025, Metropolis Healthcare share price traded 1.92% higher at ₹2,034.85 at 3:18 PM (IST). Metropolis Healthcare’s share price reached a 52-week high of ₹2,306.85 on October 10, 2024, and a 52-week low of ₹1,450.05 on January 12, 2024. As per BSE, the total traded volume for the stock stood at 0.15 lakh shares with a turnover of ₹2.98 crore.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing
Published on: Jan 6, 2025, 3:32 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
